

Medibio Signs Five-year Master Clinical Trial Agreement with Mayo Clinic

Sydney, Australia and Minneapolis, MN – 4 October 2017: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a digital health company that has developed an objective testing system to assist in the screening, diagnosing, monitoring and management of depression and other mental health disorders, is pleased to announce the signing of a five-year Master Clinical Trial Agreement with Mayo Clinic.

The agreement provides for the conduct of multiple clinical trials involving the use of one or more of Medibio's proprietary products as well as assist in development of future products. Research may be conducted at either a single or multiple U.S. locations to explore future indications for the screening, diagnosis, monitoring, and management of mental health disorders.

"We are excited to sign our 2nd agreement with Mayo Clinic and to move forward jointly on clinical trials to further expand our technology into additional areas of mental health," says Jack Cosentino, Medibio's CEO and Managing Director. ***"The clinical trials expected to come from this agreement will further solidify Medibio's research and approach on effectively screening, as well as differentiating types of mental illness, and monitoring drug therapy effectiveness and adherence for mental health patients. The Mayo Clinic provides world-renowned Psychiatry and Psychology services and is an innovator and leader in creating unique solutions that have become standard of care used by clinicians throughout the world."***

Mental health represents the largest clinical problem today with an estimated 350M people world-wide suffering from depression and is the leading cause of disability in the U.S. Given the subjective nature of the clinical assessments, less than 10% of patients receive optimal therapy following initial assessments. Under the agreement, Medibio and Mayo Clinic intend to conduct clinical studies for new product solutions to assist physicians in objectively addressing psychiatric conditions while also improving the quality, outcomes and costs associated with patient care.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a digital health company that has pioneered the use of objective biometrics to assist in the diagnosis and treatment of depression and other mental health disorders. Medibio's proprietary Digital Mental Health Platform uses advanced, cloud-based analytics to enable GPs and mental health clinicians to cost-effectively screen, precisely diagnose, and objectively confirm treatment effectiveness to better manage patients. Medibio's technology also provides an objective

method for the assessment of stress and mental well-being that can be translated to the non-medical workplace stress/well-being, wearable technology, and app markets. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market www.otcmarkets.com and www.asx.com.au.

To learn more about Medibio visit www.Medibio.com.au

– ENDS –

Further Information: Website: www.medibio.com.au	
Medibio Shareholder Enquiries: Jack Cosentino CEO and Managing Director Medibio Limited jack.cosentino@medibio.com.au T: +1 (952) 465 4787	Australian Media Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231